FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 5 of 34
Aug 5, 2026A delayed report of a second child fatality linked to a gene-editing clinical trial in China is causing widespread concern and industry criticism. This analysis delves into the ongoing debate about trial transparency, ethical oversight, and evolving global standards for next-generation therapeutics.
Dr. Alex Morgan
Aug 5, 2026Eastern Congo is facing one of its gravest public health emergencies as Ebola claims over 1,700 lives in what experts now describe as the fastest-growing outbreak of the disease. This situation presents unprecedented challenges for healthcare providers, local authorities, and the international response infrastructure, raising critical questions about outbreak preparedness, the role of trust in communities, and the global need for coordinated intervention.
Dr. Alex Morgan
Aug 4, 2026As scrutiny on drug pricing intensifies, a recent study argues that the federal exemption allowing orphan drugs to avoid Medicare price negotiations may not be warranted in all cases. Policymakers, industry, and patients face difficult questions about balancing incentives for rare disease drug development with controlling public health spending.
Michael Torres
Aug 4, 2026With the Health Resources and Services Administration (HRSA) aiming to reinvigorate 340B drug discount rebates, hospitals and providers react with apprehension about the program’s far-reaching administrative and financial implications. Drawing lessons from prior legal setbacks, this move signals renewed federal focus on cost containment and compliance in a strained sector.
Sophia Reynolds
Aug 3, 2026The announcement of the first cyclospora-related deaths in the United States underscores both the complexity of foodborne outbreaks and the critical challenges faced by public health agencies as they rush to contain and investigate the spread. This in-depth article explores the background of cyclospora, the specifics of the Michigan outbreak, and broader implications for future prevention and policy.
Dr. Priya Nandakumar
Aug 3, 2026A simmering contract dispute between Sentara Health and Anthem threatens to upend insurance coverage for hundreds of thousands of Virginians. The standoff, centered on rate renegotiations, highlights the stakes involved in payer-provider dynamics and the potential consequences for patients, providers, and the regional health ecosystem.
Dr. Priya Nandakumar
Aug 3, 2026As the FDA launches its ambitious Trialblazer initiative to modernize the clinical trial landscape, industry voices call for more comprehensive streamlining of the investigational new drug (IND) application process. Experts warn that while the program is a step forward, significant barriers remain that could blunt its intended impact on biopharmaceutical innovation.
Sophia Reynolds
Aug 3, 2026The proposed Senate action aims to serve as a safeguard against the politicization of federal research grant allocation—a move that has spurred debate across the scientific community. As federal research funding often underpins innovation in biotech, medicine, and the broader sciences, this policy battle offers a window into the ongoing tension between government oversight and scientific autonomy.
Sophia Reynolds
Aug 2, 2026The Michigan Supreme Court ruled that regulators can move forward with an investigation into whether Eli Lilly charged excessively high prices for insulin products. This ruling is set to have far-reaching implications for pharmaceutical companies, patient access, and future regulatory strategies related to drug pricing and public health.
Sophia Reynolds
Aug 1, 2026With new leadership nominees advancing and persistent gaps in infectious disease monitoring, U.S. health agencies face the twin challenges of maintaining readiness and driving reform. Federal statements point to recognition of existing limitations and provide insight into evolving health policy priorities.
Michael Torres
Jul 31, 2026The rare disease and gene therapy sector is witnessing increasing regulatory oversight as UniQure advances its Huntington’s disease gene therapy toward an FDA advisory committee review. The company’s experience reflects broader jitters in the biopharma landscape, especially after the FDA’s recent hesitation with assets from Replimune and Capricor.
Emily Carter
Jul 31, 2026The FDA advisory panel’s 10 to 3 vote in favor of Replimune’s immunotherapy, used in combination with Bristol Myers Squibb’s Opdivo for advanced melanoma, demonstrates the complexity of regulatory decision-making where clinical data present significant challenges. The trial design, deliberations, and broader industry implications are explored in depth.
Daniel ChoMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.